Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Niu Technologies – Another EV Upstart From China; This One Has Zest

Niu Tech (NIU): Where Are Your Pedals? Not Useful But Required Now

Meituan Dianping (美团点评) IPO: New Data, Mobike, Liquidity and Refined Valuation (Part 4)

Meituan Dianping (美团点评) IPO: Thoughts on Valuation - The Market Structure and the Variables (Part 3)

Meituan Dianping IPO: Understand the Moat From 3 Company Milestones

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<p>Meituan Dianping listed today and is now trading 6% above its IPO price. We have extensively covered the name since beginning of the year.</p>
<p>In this insight, we will do a recap of our previous insight, analyse the placement results and its implication on liquidity, and comment on current valuations.</p>

Meituan Dianping listed today and is now trading 6% above its IPO price. We have extensively covered the name since beginning of the year.
In this insight, we will do a recap of our previous insight, analyse the placement results and its implication on liquidity, and comment on current valuations.

Meituan Dianping (美团点评) Post-IPO Lunch-Bite: Near Term Upside and The Liquidity Angle